FWD-K01 / Shenzhen Forward Pharma - LARVOL DELTA

Sotorasib Plus Panitumumab in Refractory KRAS G12C-Mutated Colorectal Cancer (YouTube) - "Marwan G. Fakih, MD...highlights his recent publication in NEJM on sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. He provides background on the current treatment pathways for patients with KRAS G12C-mutated disease who are refractory to chemotherapy, details the design and intended outcomes of the study, and what the results show generally about the effectiveness of sotorasib plus panitumumab as well as specifically about the varying dosages administered."

Video

Sotorasib Plus Panitumumab in Refractory KRAS G12C-Mutated Colorectal Cancer (YouTube) - "Marwan G. Fakih, MD...highlights his recent publication in NEJM on sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. He provides background on the current treatment pathways for patients with KRAS G12C-mutated disease who are refractory to chemotherapy, details the design and intended outcomes of the study, and what the results show generally about the effectiveness of sotorasib plus panitumumab as well as specifically about the varying dosages administered."

Video

Study identifies promising treatment for advanced colorectal cancer (City of Hope) - "'This is the first Phase 3 clinical trial to show a benefit over standard of care in patients with the KRAS G12C mutation whose cancer progressed after receiving standard chemotherapy. The efficacy results from our study are promising in this population with unmet needs and should set a new standard of care for metastatic colorectal cancer patients with the KRAS G12C mutation who progressed following prior standard treatments,' said Marwan Fakih..."

Media quote

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM https://nejm.org/doi/full/10.1056/NEJMoa2308795?query=featured_home Presidential ESMO session today by Dr. Pietrantonio! CodeBreaK 300 Phase 3 trial provides Level One Evidence for Soto + Pmab in KRAS G12C in refractory MCRC.

Dr Bekaii-Saab on Treatment Evolutions in KRAS G12C–Mutant and HER2-Overexpressing CRC (OncLive) - "Another exciting focus within CRC is the subgroup of patients characterized by HER2 amplification, which accounts for approximately 3% to 4% of metastatic CRC cases, Bekaii-Saab continues. This subgroup has seen much progress in the past year. Notably, in January 2023, the FDA granted approval to the combination of tucatinib (Tukysa) and trastuzumab (Herceptin)for patients with RAS wild-type disease with HER2 overexpression, he explains. This approval followed the promising results of the phase 2 MOUNTAINEER trial (NCT03043313), which demonstrated high response rates, enduring responses, and favorable outcomes in patients who received this treatment approach, Bekaii-Saab explains."

Regulatory • Video

Advances in Biomarker Testing and Targeted Therapies in NSCLC : Episode 10 Adagrasib for Patients with KRAS G12C–Mutant NSCLC (OncLive) - "Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors."

Biomarker • Video

Dr. Irina Veytsman @MedStarWHC will discuss the current management of #KRAS G12C mutant NSCLC at #DCLung23 on Saturday October 7. Sotorasib and adagrasib now approved - newer agents coming - how should they be used? Full agenda, faculty and registration at https://medstarhealth.org/dclung23

Adagrasib Induces Durable Efficacy in KRAS G12C-Mutant NSCLC (Targeted Oncology) - '"Adagrasib demonstrated durable clinical benefit [and] there were no new safety signals,' said Gadgeel...'The drug appeared to be well tolerated particularly in patients who received the drug for more than 1 year'....'Importantly, even with the long-term follow-up, none of the 12 patients who started the drug within 30 days of immunotherapy [experienced] grade 3 or greater hepatotoxicity and only 1 discontinued the drug due to grade 3 hepatotoxicity,' Gadgeel said.

Media quote

KRAS G12C inhibitors for GI cancer (YouTube) - "John Strickler, MD...discusses how KRAS G12C inhibitors other than sotorasib and adagrasib have more recently entered clinical testing. Encouraging single agent data for KRAS G12C inhibitors have been noted in colon and pancreatic cancer settings. The addition of EGFR inhibitors for colorectal cancer has also shown promising results. Future study will focus on other KRAS G12C inhibitors and other inhibitors that target other types of GI cancer. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain."

Interview • Video

Advances in targeted therapies for colorectal cancer (YouTube) - "John Strickler, MD...gives an overview of how strategies targeting BRAF have included clinical testing for V600E mutations in recent years. KRAS G12C inhibitors are showing striking activity for KRAS G12C-mutant colorectal cancer. Additionally, anti-HER2 treatment has shown interesting results in patients with HER2-positive colorectal cancer. In the USA, there is an FDA anti-HER2 approved regimen. In the future, in order to widen the scope of understanding surrounding GI cancers, other KRAS variants need to be studies, such as KRAS G12D. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain."

Interview • Video

Expert Point of View: Dustin Deming, MD (THE ASCO POST) - "As Dr. Deming noted, there are multiple options for patients in the refractory setting, with treatment often determined by subtype. Patients with RAS/RAF wild-type tumors, KRAS G12C mutations, BRAF V600 mutations, mismatch repair deficiency/microsatellite instability, and HER2 amplification can be biomarker-selected for targeted agents that have proven efficacy in these subtypes. For patients lacking these targets, the standard nontargeted treatment options are trifluridine/tipiracil and regorafenib, for which median progression-free survival is about 2 months. Regarding emerging approaches, the findings from phase II studies show that disease progression can be further delayed (to around 4 months) with trifluridine/tipiracil plus bevacizumab1,2 and with fruquintinib."

Media quote

Improving HER2 Biomarker Testing in mCRC - Episode 7 - Emphasizing HER2 Testing as A Premier Diagnostic Approach To mCRC (AJMC) - "Testing prioritization and frequency are highlighted in Dr Ciombor's final insights for this HER2 biomarker focus.Molecular testing is 1 piece of the pie in terms of how I consider what the best treatment is for our patient, but it’s becoming an increasingly important piece of the pie. Knowledge is critical in making sure that we’re treating patients effectively."

Video